We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-24.99%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$160M
AUM Growth
-$78.8M
Cap. Flow
-$21.6M
Cap. Flow %
-13.46%
Top 10 Hldgs %
42.9%
Holding
67
New
14
Increased
18
Reduced
12
Closed
14
Avg Time Held
3 quarters
Top 10 Avg Time Held
1.9 quarters
Top 20 Avg Time Held
2.8 quarters

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.49M
2
CMRX icon
Chimerix, Inc.
CMRX
+$4.41M
3
TVRD icon
Tvardi Therapeutics
TVRD
+$3.55M
4
IMMU
Immunomedics Inc
IMMU
+$2.33M
5
SAGE icon
Sage Therapeutics
SAGE
+$2.29M

Top Sells

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$6.24M
2
CEMP
Cempra, Inc.
CEMP
+$6.23M
3
TNXP icon
Tonix Pharmaceuticals
TNXP
+$4.33M
4
AVGR icon
Avinger, Inc. Common Stock
AVGR
+$4.32M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 88.12%
2 Miscellaneous 11.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AXGN icon
1
Axogen
AXGN
$2.18B
$11.4M 7.09%
2,120,000
– –
2015 Q1
4 quarters
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$7.99M 4.98%
1,250,000
-60,000
-5% -$336K
2013 Q4
9 quarters
RARE icon
3
Ultragenyx Pharmaceutical
RARE
$1.51B
$6.96M 4.34%
110,000
– –
2014 Q2
7 quarters
KYNB icon
4
Kyntra Bio
KYNB
$24.8M
$6.92M 4.31%
13,000
– –
2014 Q4
5 quarters
GNMX icon
5
DELISTED
Aevi Genomic Medicine Inc
GNMX
$6.85M 4.27%
1,557,700
+167,700
+12% +$690K
2014 Q4
5 quarters
ADMS
6
DELISTED
Adamas Pharmaceuticals
ADMS
$6.06M 3.78%
320,000
+130,000
+68% +$2.19M
2015 Q1
4 quarters
TVRD icon
7
Tvardi Therapeutics
TVRD
$14.1M
$5.32M 3.32%
23,750
+11,889
+100% +$3.55M
2014 Q4
5 quarters
SAGE icon
8
DELISTED
Sage Therapeutics
SAGE
$5.29M 3.3%
165,000
+65,000
+65% +$2.29M
2015 Q3
2 quarters
AMAG
9
DELISTED
AMAG Pharmaceuticals
AMAG
$5.15M 3.21%
220,000
+70,000
+47% +$1.66M
2015 Q1
4 quarters
HROW icon
10
Harrow
HROW
$1.09B
$4.96M 3.09%
1,250,000
+45,000
+4% +$219K
2014 Q3
6 quarters
ASRT icon
11
DELISTED
Assertio
ASRT
$4.53M 2.82%
5,417
+417
+8% +$387K
2015 Q4
1 quarter
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.84B
$4.26M 2.66%
+105,000
New +$4.49M
2016 Q1
0 quarters
BPMC icon
13
DELISTED
Blueprint Medicines
BPMC
$3.97M 2.48%
220,000
-55,000
-20% -$954K
2015 Q3
2 quarters
GERN icon
14
Geron
GERN
$784M
$3.87M 2.41%
1,325,000
-500,000
-27% -$1.5M
2014 Q3
6 quarters
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.85M 2.4%
590,000
+90,000
+18% +$580K
2015 Q2
3 quarters
CDXS icon
16
Codexis
CDXS
$154M
$3.67M 2.29%
1,178,500
-421,500
-26% -$1.62M
2014 Q1
8 quarters
TGTX icon
17
TG Therapeutics
TGTX
$8.46B
$3.54M 2.21%
415,000
+115,000
+38% +$1.01M
2015 Q3
2 quarters
CMRX icon
18
DELISTED
Chimerix, Inc.
CMRX
$3.45M 2.15%
+675,000
New +$4.41M
2016 Q1
0 quarters
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.38M 2.11%
80,000
-25,000
-24% -$1.27M
2014 Q3
6 quarters
IMMU
20
DELISTED
Immunomedics Inc
IMMU
$3.31M 2.07%
1,325,000
+1,035,000
+357% +$2.33M
2015 Q4
1 quarter
XENE icon
21
Xenon Pharmaceuticals
XENE
$3.47B
$2.8M 1.74%
400,000
+100,000
+33% +$719K
2015 Q3
2 quarters
AMRN icon
22
Amarin Corp
AMRN
$254M
$2.69M 1.68%
88,000
– –
2015 Q1
4 quarters
INDP icon
23
Indaptus Therapeutics
INDP
$325M
$2.63M 1.64%
285
+4
+1% +$37.2K
2015 Q3
2 quarters
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.45M 1.53%
1,095
+215
+24% +$462K
2015 Q4
1 quarter
EGRX icon
25
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.43M 1.52%
60,000
-25,000
-29% -$1.59M
2015 Q2
3 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opaleye Management held 67 positions worth $160M, down 33% from $239M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management withdrew a net $21.6M in Q1 2016, closing 14 positions and reducing 12 holdings. Its most notable exit was RELYPSA INC COM, an estimated $6.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Agios Pharmaceuticals worth $4.26M.

  • Opaleye Management's largest Q1 2016 buy was Agios Pharmaceuticals: 105,000 shares worth $4.26M.
  • Opaleye Management added most to Tvardi Therapeutics in Q1 2016, an estimated $3.55M increase.
  • Opaleye Management's biggest Q1 2016 reduction was Supernus Pharmaceuticals, cutting an estimated $3.85M.
  • Opaleye Management fully exited RELYPSA INC COM in Q1 2016, selling an estimated $6.24M.
  • Opaleye Management's ten largest holdings make up 43% of its $160M portfolio in Q1 2016.
  • Opaleye Management opened 14 new positions and closed 14 in Q1 2016.
  • Opaleye Management's portfolio value fell 33% quarter-over-quarter to $160M.

Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.